Aurinia Research Development from 2010 to 2026
| AUPH Stock | USD 14.44 0.18 1.26% |
Research Development | First Reported 1999-03-31 | Previous Quarter 7.4 M | Current Value 8.4 M | Quarterly Volatility 4.4 M |
Check Aurinia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.5 M, Interest Expense of 5.8 M or Selling General Administrative of 190.7 M, as well as many indicators such as Price To Sales Ratio of 4.67, Dividend Yield of 0.0 or PTB Ratio of 3.22. Aurinia financial statements analysis is a perfect complement when working with Aurinia Pharmaceuticals Valuation or Volatility modules.
Aurinia | Research Development | Build AI portfolio with Aurinia Stock |
The Research Development trend for Aurinia Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Aurinia Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Aurinia Pharmaceuticals' Research Development Growth Pattern
Below is the plot of the Research Development of Aurinia Pharmaceuticals over the last few years. It is Aurinia Pharmaceuticals' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aurinia Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Aurinia Research Development Regression Statistics
| Arithmetic Mean | 26,037,652 | |
| Geometric Mean | 16,535,218 | |
| Coefficient Of Variation | 73.38 | |
| Mean Deviation | 16,706,993 | |
| Median | 21,699,799 | |
| Standard Deviation | 19,107,477 | |
| Sample Variance | 365.1T | |
| Range | 51.4M | |
| R-Value | 0.63 | |
| Mean Square Error | 234.2T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 2,389,249 | |
| Total Sum of Squares | 5841.5T |
Aurinia Research Development History
About Aurinia Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Aurinia Pharmaceuticals' Research Development, to determine how well the company is positioned to perform in the future. Although Aurinia Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Research Development | 23.9 M | 21.7 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is there potential for Biotechnology market expansion? Will Aurinia introduce new products? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.3 | Earnings Share 0.56 | Revenue Per Share | Quarterly Revenue Growth 0.084 | Return On Assets |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Aurinia Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aurinia Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Aurinia Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.